Phase I
The drug developed by Alkermes took a lot of flack but proved effective in a recent study.
As the world watches big pharma companies take on the challenges of developing a viable therapy for ALZ’s disease, smaller companies are also attempting to blaze a treatment trail in the neurodegenerative market.
Instead of targeting a molecule called CD19 on the surface of the cancer cells, the new therapy targets a molecule called CD22.
Researchers are making great headway against cancer, even though it’s currently still the second-leading cause of death in the U.S.
CAR-T is a hot new area and there are companies hot on Gilead’s tail, namely Juno, in a partnership with Celgene, and Novartis.
Moderna announced that it has dosed its first patient in a Phase I trial of mRNA-4157, a mRNA-based personalized cancer vaccine.
Barely a week after announcing it was moving into a new corporate headquarters, Sangamo announced it has dosed the first patient in its Phase I/II gene therapy trial.
Two months after positive preliminary data showed sitravatinib in combination with Opdivo demonstrated some efficacy in treating patients with NSCLC, Mirati said it will reprioritize its R&D to focus.
Neurotoxicity killed JCAR015 right along with 5 patients in the lead pivotal study, derailing Juno Therapeutics.
BMS is pushing forward with its internal IDO1 program and showing off early-stage data from its Phase I/IIa combination trial of Opdivo plus BMS-986205, an IDO1 inhibitor.
PRESS RELEASES